-
Featured Authors
-
Archives
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008
-
Meta
Tag Archives: Global Health
Biotech, Gates Foundation, and Global Health
Great interview by Gene Quinn with Erik Iverson, Associate General Counsel with the Bill & Melinda Gates Foundation. A summary article is on BIOtech Now and the full interview can be found on IPWatchdog.com. Highlights: Iverson told me in no uncertain terms, “[A] fundamental premise at the foundation is that we absolutely respect intellectual property rights. We recognize their importance and we certainly recognize the importance of companies and their involvement in developing products and having Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Bill & Melinda Gates Foundation, Bill Gates, BIO, biotechnology, developing countries, Erik Iverson, Gene Quinn, Global Health, global health, humanitaria, humanitarian, Intellectual Property, IPWatchdog, life science, Neglected Diseases, patent
Tags: Bill & Melinda Gates Foundation, Bill Gates, BIO, biotechnology, developing countries, Erik Iverson, Gene Quinn, Global Health, global health, humanitaria, humanitarian, Intellectual Property, IPWatchdog, life science, Neglected Diseases, patent
Bayh-Dole Podcast moderated by BIO with AUTM and patient advocate
Lila Feisee, Vice President for Global Intellectual Property Policy at BIO, moderated a podcast on the benefits of the Bayh-Dole Act and the need to maintain flexibility in our nation’s technology transfer system. She was joined by: Dr. Ashley Stevens, Special Assistant to the Vice President for Research Technology Development and Senior Research Associate at the Institute for Technology Entrepreneurship & Commercialization at the Boston University School of Management. He also serves as President of Read More >
AUTM’s 2010 Better World Report Highlights
AUTM released their Better World Report for 2010 highlighting academic innovations commercially developed through technology transfer that are improving the quality of life. Here is a quote from their press release. A device that allows the blind to ―see‖ via electrical pulses applied to the tongue…a collagen scaffold to treat damaged joints…a new vaccine to prevent shingles…an artificial lung that provides patients with both mobility and comfort during treatment…a program that vastly improves literacy among Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: Association of Technology Transfer Managers, AUTM, Bayh-Dole, BIO, biotechnology, economic development, federally funded research, Global Health, government funded research, healthcare, Licensing technology, modern medicine, new drug development, NIH, patents, Research and Development, Senator Birch Bayh, Senator Dole
Tags: Association of Technology Transfer Managers, AUTM, Bayh-Dole, BIO, biotechnology, economic development, federally funded research, Global Health, government funded research, healthcare, Licensing technology, modern medicine, new drug development, NIH, patents, Research and Development, Senator Birch Bayh, Senator Dole
Pathogens and the Nagoya Protocol of the Convention on Biological Diversity
Some nations have argued that the recent Nagoya Protocol of the Convention of Biological Diversity (CBD) includes pathogens. The inclusion of pathogens in the Nagoya Protocol could adversely affect the world’s ability to control outbreaks of infectious disease. The following reasons demonstrate why pathogens are not and should not be included in the Nagoya Protocol. Contrary to the Mission of the CBD: The three main objectives of the CBD are; “The conservation of biological Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: ABS, ABS Protocol, Access and Benefit Sharing, access and benefit sharing protocol, access and benefits, CBD, conservation, Convention on Biological Diversity, Global Health, infectious disease, Nagoya Protocol, outbreak, Pandemic, Pathogen, Pathogens, sustainable use, WHO, World Health Organization
Tags: ABS, ABS Protocol, Access and Benefit Sharing, access and benefit sharing protocol, access and benefits, CBD, conservation, Convention on Biological Diversity, Global Health, infectious disease, Nagoya Protocol, outbreak, Pandemic, Pathogen, Pathogens, sustainable use, WHO, World Health Organization
IPWatchdog.com interview of Bayh-Dole insider
A great article from IPWatchdog.com giving Joe Allen’s (a Birch Bayh staffer) insider perspective on the passage of the Bayh-Dole Act. The Article’s Introduction: William Shakespeare once wrote: There is a tide in the affairs of men Which taken at the flood, leads on to fortune; Omitted, all the voyage of their life Is bound in shallows and in miseries. See Julius Caesar. We caught the tide– but just barely. That the Bayh-Dole Act passed was amazing. Read More >
